NCT03554304 - Evaluate the Effect of WCK 5222 on the QT/QTc Interval in Healthy Volunteers | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 9, 2017

Primary Completion Date

June 5, 2017

Study Completion Date

October 6, 2017

Conditions

QT/QTc Interval in Healthy Volunteers

Interventions

DRUG

WCK 5222

FEP-ZID IV solution administered as either a 30- or 60-minute IV infusion)

DRUG

IV placebo matched to WCK 5222 / Moxifloxacin IV solution

"Placebo (IV placebo matched to FEP-ZID IV solution) and~1 placebo capsule matched to moxifloxacin overencapsulated tablet"

DRUG

Moxifloxacin 400-mg

Moxifloxacin 400-mg positive control (overencapsulated tablet)

Trial Locations (1)

Spaulding Clinical Research, West Bend